Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – Initial Jobless Claims

✓ 08:30 AM ET – Continuing Jobless Claims

✓ 08:30 AM ET – Exports

✓ 08:30 PM ET – Imports

PREMARKET SNAPSHOT 📈

Nasdaq 100 leads the pack with a gain of 0.21% while Dow Jones trails with a slight decline of -0.10%.

SECTOR SNAPSHOT ✨

Most sectors are mixed today, with Consumer Staples leading the decline at -1.10% and Communication Services experiencing the strongest gains at +0.71%.

Unusual Volume

📈 Kintara Therapeutics Inc (KTRA) jumped 63.35% to $0.16 on a whopping 223.73 million shares traded after it announced a definitive agreement with TuHURA Biosciences, Inc. for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline.

📈 Investors went wild, sending C3is Inc (CISS) stock soaring 24.21% to $0.05 on a massive volume of 150.55 million shares.

📈 Abnormal activity shook Next.e.GO N.V. (EGOX), pushing it up 30.38% to $0.03 on a whopping 127.64 million shares traded after announcing its decision to also file an application for opening of insolvency proceedings with the competent district court of Aachen.

📈 SINTX Technologies Inc (SINT) stock recently closed -43.77% lower at $0.02 on substantial volume of 84.51 million shares. This unusual activity came after the company announced pricing of $1.5 million public offering of common stock.

📈 ARCA biopharma Inc (ABIO) increase by 90.06% in a single trading session, with abnormally high trading volume of 80.69 million shares after announcing a definitive agreement with Oruka Therapeutics to combine the companies in an all-stock transaction.

Premarket Movers

TRACON Pharmaceuticals, Inc. (TCON) experiences a substantial 3.46% surge in pre-market trading after providing update on ongoing ENVASARC phase 2 pivotal trial.

Reliance Global Group, Inc. (RELI) sees a significant 82.92% increase, reaching a pre-market price of $0.67 after reporting financial results for the year ended December 31, 2023.

HUB Cyber Security Ltd. (HUBC) demonstrates a noteworthy 37.66% surge, with a pre-market price of $0.98. The company announced the successful acquisition for cash of Qpoint Technologies.

Important FDA 

Recently Announced

Regeneron Pharmaceuticals (REGN) recently faced setbacks with the FDA issuing Complete Response Letters (CRLs) for their drug odronextamab's Biologics License Application (BLA) for lymphoma treatment.

Esperion Therapeutics (ESPR) achieved a milestone with FDA approval broadening labels for NEXLETOL and NEXLIZET, allowing heart attack prevention regardless of statin use, highlighting ESPR's dedication to cardiovascular health.

VANDA PHARMACEUTICALS (VNDA) celebrated FDA approval for expanded use of Fanapt in bipolar I disorder treatment, showcasing VNDA's commitment to addressing mental health needs and expanding treatment options.

Upcoming Announcements

Legend Biotech Corporation, (LEGN) is awaiting the FDA decision on the expanded use of Carvykti (sBLA) to include earlier treatment of patients with relapsed or refractory multiple myeloma. The event is scheduled for April 5, 2024, with the outcome currently pending.

Supernus Pharmaceuticals, Inc. (SUPN) is also awaiting the FDA decision on SPN-830 (resubmitted NDA) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease. Like LEGN, the event is slated for April 5, 2024, and the outcome is pending.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.